Contract outfit TKL Research has opened a new early-phase-focused clinic in Northern New Jersey, looking to capitalize on demand for Phase I services as it expands its footprint.
Located in Fair Lawn, NJ, TKL's new shop is a 25,000-square-foot operation with a 30-bed pharmacology unit for Phase I studies and exam rooms for outpatient work, the company said. The clinic is 70% larger than TKL's Phase II-IV facility in nearby Rochelle Park, according to the CRO, and the company is hoping to leverage its experience in early-stage study enrollment to snag a share of the Phase I services market.
"The Fair Lawn research facility will enable us to meet the increased demand for our services in the diseased-state populations for Phase I clinical trials, in which we have strong patient recruitment expertise," CEO Jon Anderson said in a statement, adding that TKL's latest location is well-situated in the New York City metropolitan area, likely easing the enrollment process.
TKL's latest expansion follows its 2010 move into Europe, where it bought an equity stake in Germany's Proinnovera to tap the overseas market.
The CRO began with a focus on dermatology studies but has since expanded to employ experts in gastroenterology, respiratory, endocrinology and women's health.
- read the release